BridgeBio Pharma, Inc. issued $632.5 million in convertible senior notes on January 21, 2026, to be used for repurchasing shares and general corporate purposes. The notes yield 0.75% interest and mature in 2033, with $82.5 million allocated to buy back 1,081,825 shares at $76.26 each.